clinical trial · NCT06895928
A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.·phase2·recruiting·n = 400
Advanced Solid TumorsSHR-A2102Bevacizumab InjectionAdebelimab InjectionAmetinib Mesylate TabletsOsimertinib Mesylate Tablets
brief summary
The study is being conducted to evaluate the safety, tolerability and efficacy of SHR-A2102 with other antitumor therapies in advanced solid tumors to explore the reasonable dosage, safety and efficacy of SHR-A2102 for advanced solid tumors.
started
Mar 28, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Apr 22, 2025
official title
A Phase II, Multicenter, Open-Label Study of Safety, Tolerability and Efficacy of SHR-A2102 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol